Overall, our current study reveals that bilirubin is a microenvironmental factor that can inhibit the activity of vemurafenib via reactivation of the ERK1/2-MNK1 signaling, which may help to develop new anti-tumor strategies in patients with BRAF mutant melanoma. The gene discussed is BRAF; the disease is neoplasm.